Skip to content

Avalo Therapeutics AVTX Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$19.63M-43.1%-$13.72M+55.2%-$30.63M-47.5%-$20.77M-57.9%-$13.15M+62.8%
$17K+6.3%$16K-72.9%$59K-56.0%$134K-0.7%$135K+98.5%
$3.58M-20.7%$4.51M+42.9%$3.15M+16.0%$2.72M-16.1%$3.24M+11.6%
-$17.69M-24.2%-$14.25M+12.9%-$16.37M-43.7%-$11.39M-20.4%-$9.46M+37.1%
$25.51M$0+100%-$13.26M+81.3%-$70.86M$0
$1.4M+104%$687K-95.2%$14.37M+3,164%-$469K$0-100%
$9.21M+183%-$11.16M+26.9%-$15.26M+81.6%-$82.72M-775%-$9.46M-118%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Avalo Therapeutics generate?
Avalo Therapeutics (AVTX) generated -$59.7M in operating cash flow over the trailing twelve months.
Where does Avalo Therapeutics's cash flow data come from?
Every line is extracted from Avalo Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.